Results expand our understanding of glioma etiology associated with IDH1 and altered cellular metabolism, identifying new mechanistic links and vulnerabilities, which could be targeted in future clinical trials for glioma IDH-wildtype. This evidence concerns the gene IDH1 and central nervous system cancer.